S100B and major depressive disorder: The aim of this study was (i) to determine if mBDNF and S100B plasma levels were changed after ketamine treatment and (ii) to evaluate the relationship between clinical outcomes and levels of these plasma proteins in SSRI-resistant MDD patients.